0001209191-11-042167.txt : 20110803 0001209191-11-042167.hdr.sgml : 20110803 20110802203338 ACCESSION NUMBER: 0001209191-11-042167 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20110803 DATE AS OF CHANGE: 20110802 EFFECTIVENESS DATE: 20110803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Trimel Pharmaceuticals Corp CENTRAL INDEX KEY: 0001527246 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-163870 FILM NUMBER: 111005065 BUSINESS ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 BUSINESS PHONE: 1 416 679 0771 MAIL ADDRESS: STREET 1: 2488 DUNWIN DRIVE CITY: MISSISSAUGA STATE: A6 ZIP: L5L 1J9 D 1 primary_doc.xml X0704 D LIVE 0001527246 Trimel Pharmaceuticals Corp 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 1 416 679 0771 ONTARIO, CANADA None None Corporation true 2009 Bruce D. Brydon 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Executive Officer Director Kenneth G. Howling 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Executive Officer Mark L. Thompson 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Executive Officer Rolf Reininghaus 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Executive Officer Director Robert Podruzny 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Director Douglas Deeth 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Director Larry Davis 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Director Stephen Gregory 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Director James Butler 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Director Jeffrey Sherman 2488 Dunwin Drive Mississauga A6 ONTARIO, CANADA L5L 1J9 Director Eugene Melnyk Beach House, Crane St. Philip C8 BARBADOS BB18079 Promoter Pharmaceuticals Decline to Disclose 06 false 2011-07-14 true true true true true Securities were issued in exchange for previously issued securities of Trimel BioPharma Holdings Inc. pursuant to an amalgamation agreement dated March 2, 2011 (as amended on each of June 14, 2011 and June 30, 2011). 0 12026355 6847846 5178509 "Total Remaining to be Sold" includes amounts related to common shares of filer to be issued upon exercise of warrants included in units issued on July 14, 2011. false 16 0 0 0 false Trimel Pharmaceuticals Corp /s/ Kenneth G. Howling Kenneth G. Howling Chief Financial Officer 2011-08-02